

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS TIBIAL NERVE STIMULATION
POLICY NUMBER	MP-1.134

Original Issue Date (Created):	9/1/2012
Most Recent Review Date (Revised):	4/26/2018
Effective Date:	11/1/2018

[POLICY RATIONALE](#)
[DISCLAIMER](#)
[POLICY HISTORY](#)

[PRODUCT VARIATIONS](#)
[DEFINITIONS](#)
[CODING INFORMATION](#)

[DESCRIPTION/BACKGROUND](#)
[BENEFIT VARIATIONS](#)
[REFERENCES](#)

I. POLICY

Percutaneous tibial nerve stimulation for an initial 12-week course is considered **medically necessary** for individuals with non-neurogenic urinary dysfunction including overactive bladder who have both:

- failed behavioral therapy following an appropriate duration of 8 to 12 weeks without meeting treatment goals; and
- failed pharmacologic therapy following 4 to 8 weeks of treatment without meeting treatment goals.

Maintenance therapy using monthly percutaneous tibial nerve stimulation is considered **medically necessary** for individuals following a 12-week initial course of percutaneous tibial nerve stimulation that resulted in improved urinary dysfunction meeting treatment goals.

Percutaneous tibial nerve stimulation is considered **investigational** for all other indications, including but not limited to the following:

- Neurogenic bladder dysfunction
- Fecal incontinence

There is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure for these indications.

POLICY GUIDELINES

Patients may be considered to have failed behavioral therapies following an appropriate duration of 8 to 12 weeks without meeting treatment goals (Gormley et al [2015]).

Patients may be considered to have failed pharmacologic therapies following 4 to 8 weeks of treatment without meeting treatment goals (Gormley et al [2015]).

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS TIBIAL NERVE STIMULATION
POLICY NUMBER	MP-1.134

Annual evaluation by a physician may be performed to ensure efficacy is continuing for maintenance percutaneous tibial nerve stimulation treatments.

Cross-references:

MP-1.033 Sacral Nerve Neuromodulation/Stimulation and Pelvic Floor Stimulation Devices

MP-6.050 Percutaneous Electrical Nerve Stimulation (PENS) and Percutaneous Neuromodulation Therapy

MP-2.064 Biofeedback and Neurofeedback Therapy

MP-1.109 Periureteral Bulking Agents as Treatment of Vesicoureteral Reflux

MP-2.096 Electromyography (EMG) (Needle and Non-Needle) of the Anal or Urethral Sphincter

II. PRODUCT VARIATIONS

[TOP](#)

This policy is applicable to all programs and products administered by Capital BlueCross unless otherwise indicated below.

FEP PPO - Refer to FEP Medical Policy Manual MP-7.01.106 Posterior Tibial Nerve Stimulation for Voiding Dysfunction. The FEP Medical Policy manual can be found at: www.fepblue.org

III. DESCRIPTION/BACKGROUND

[TOP](#)

VOIDING DYSFUNCTION

Common causes of voiding dysfunction are pelvic floor neuromuscular changes (eg, from pregnancy, childbirth, surgery), inflammation, medication (eg, diuretics, anticholinergics), obesity, psychogenic factors, and disease (eg, multiple sclerosis, spinal cord injury, detrusor hyperreflexia, diabetes with peripheral nerve involvement).

Altering the function of the posterior tibial nerve with percutaneous tibial nerve stimulation (PTNS) is believed to improve voiding function and control. The mechanism of action is believed to be retrograde stimulation of the lumbosacral nerves (L4-S3) via the posterior tibial nerve located near the ankle. The lumbosacral nerves control the bladder detrusor and perineal floor. Overactive bladder is voiding dysfunction that is characterized by urinary frequency, urgency, urge incontinence, and nonobstructive retention.

Treatment

Approaches to the treatment of incontinence differentiate between urge incontinence and stress incontinence. Conservative behavioral management such as lifestyle modification (eg, dietary changes, weight reduction, fluid management, smoking cessation) along with pelvic floor exercises and bladder training are part of the initial treatment of overactive bladder symptoms and both types of incontinence. Pharmacotherapy is another option, and different medications target different symptoms. Some individuals experience mixed incontinence.

POLICY TITLE	PERCUTANEOUS TIBIAL NERVE STIMULATION
POLICY NUMBER	MP-1.134

The current indication cleared by the U.S. Food and Drug Administration (FDA) for PTNS is overactive bladder and associated symptoms of urinary frequency, urinary urgency, and urge incontinence.

The procedure for PTNS consists of the insertion of a needle above the medial malleolus into the posterior tibial nerve followed by the application of low-voltage (10 mA, 1-10 Hz frequency) electrical stimulation that produces sensory and motor responses as evidenced by a tickling sensation and plantarflexion or fanning of all toes. Noninvasive PTNS has also been delivered with transcutaneous or surface electrodes. The recommended course of treatment is an initial series of 12 weekly office-based treatments followed by an individualized maintenance treatment schedule.

PTNS is less invasive than traditional sacral nerve neuromodulation, which has been successfully used in the treatment of urinary dysfunction but requires implantation of a permanent device. In sacral root neuromodulation, an implantable pulse generator that delivers controlled electrical impulses is attached to wire leads that connect to the sacral nerves, most commonly the S3 nerve root that modulates the neural pathways controlling bladder function.

PTNS has been proposed as a treatment for non-neurogenic and neurogenic bladder syndromes and fecal incontinence.

REGULATORY STATUS

In July 2005, the Urgent® PC Neuromodulation System was the initial device cleared for marketing by FDA through the 510(k) process for PTNS to treat patients suffering from urinary urgency, urinary frequency, and urge incontinence. Additional percutaneous tibial nerve stimulators have been cleared for marketing through the 510(k) process. They are listed in Table 1.

The Urgent® PC Neuromodulation System and NURO™ Neuromodulation System are not FDA-cleared for other indications, such as the treatment of fecal incontinence.

There is developing wireless technology for the treatment of overactive bladder, approved in Europe. BlueWind (BlueWind Medical) is a wireless, battery-less, miniature implantable neurostimulator that is activated by an external device worn at the ankle.

Table 1. FDA-Cleared Percutaneous Tibial Nerve Stimulators (FDA Product Code: NAM)

Device Name	Manufacturer	Cleared	510(k)	Indications
Urgent® PC Neuromodulation System	Uroplasty, now Cogentix Medical	Oct 2005	K052025	Indicated for treatment of urinary urgency, urinary frequency, and urge incontinence
Urgent® PC Neuromodulation System	Uroplasty, now Cogentix Medical	Jul 2006	K061333	FDA determined the 70% isopropyl alcohol prep pad contained in the kit is subject to regulation as a drug
Urgent® PC Neuromodulation System	Uroplasty, now Cogentix Medical	Aug 2007	K071822	Labeling update, intended use is unchanged
Urgent® PC Neuromodulation System	Uroplasty, now Cogentix Medical	Oct 2010	K101847	Intended use statement adds the diagnosis of overactive bladder
NURO™ Neuromodulation System	Advanced Uro-Solutions, now Medtronic	Nov 2013	K132561	Intended to treat patients with overactive bladder and associated symptoms of urinary urgency, urinary frequency, and urge incontinence

FDA: Food and Drug Administration.

POLICY TITLE	PERCUTANEOUS TIBIAL NERVE STIMULATION
POLICY NUMBER	MP-1.134

IV. RATIONALE

[TOP](#)

SUMMARY OF EVIDENCE

For individuals who have non-neurogenic urinary dysfunction including OAB who have failed behavioral and pharmacologic therapy who receive an initial course of PTNS, the evidence includes randomized sham-controlled trials, RCTs with an active comparator, and systematic reviews. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. The SUmiT and the OrBIT trials are 2 key industry-sponsored RCTs. Systematic reviews that include these trials and other published trials have found short-term improvements with PTNS. The largest, highest quality study was the double-blinded, sham-controlled SUmiT trial. It reported a statistically significant benefit of PTNS vs sham at 12 weeks. In an additional small sham-controlled trial, a 50% reduction in urge incontinent episodes was attained in 71% of PTNS group compared with 0% in the sham group. The nonblinded OrBIT trial found that PTNS was noninferior to medication treatment at 12 weeks. Adverse events were limited to local irritation effects. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have OAB syndrome that has failed behavioral and pharmacologic therapy who respond to an initial course of PTNS who receive maintenance PTNS, the evidence includes observational studies and systematic reviews. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. The SUmiT and the OrBIT trials each included extension studies that followed individuals who responded to the initial course of PTNS and continued to receive periodic maintenance therapy. There is variability in the interval between and frequency of maintenance treatments, and an optimal maintenance regimen remains unclear. There are up to 36 months of observational data available, reporting that there is a durable effect for some of these patients. While comparative data are not available after the initial 12-week treatment period, the observational data support a clinically meaningful benefit for use in individuals who have already failed behavioral and pharmacologic therapy and who respond to the initial course of PTNS. PTNS may allow such individuals to avoid more invasive interventions. Adverse events appear to be limited to local irritation for both short and long-term PTNS use. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have neurogenic bladder dysfunction who receive PTNS, the evidence includes several RCTs and a systematic review of RCTs and observational data. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Only a few RCTs evaluating tibial nerve stimulation for treating neurogenic bladder have been published to date, and all but one performed transcutaneous stimulation rather than PTNS. Studies varied widely in factors, such as the study populations and comparison interventions. Study findings have not reported that tibial nerve stimulation significantly improved incontinence symptoms and other outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS TIBIAL NERVE STIMULATION
POLICY NUMBER	MP-1.134

For individuals who have fecal incontinence who receive PTNS, the evidence includes several RCTs and systematic reviews. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. The available RCTs have not found a clear benefit of PTNS. Neither of the sham-controlled trials found that active stimulation was superior to sham for achieving the primary outcome, at least a 50% reduction in mean weekly fecal incontinence episodes. The larger sham-controlled randomized trial did find a significantly greater decrease in the absolute number of weekly incontinence episodes in the active treatment group, but the overall trial findings did not suggest the superiority of PTNS over sham treatment. Systematic reviews have not conducted pooled analyses. The evidence is insufficient to determine the effects of the technology on health outcomes.

V. DEFINITIONS

[TOP](#)

URGE INCONTINENCE is defined as leakage of urine when there is a strong urge to void.

URGENCY-FREQUENCY is an uncontrollable urge to urinate, resulting in very frequent, small volumes.

URINARY RETENTION is the inability to completely empty the bladder of urine

VI. BENEFIT VARIATIONS

[TOP](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's contract. Benefit determinations should be based in all cases on the applicable contract language. Medical policies do not constitute a description of benefits. A member's individual or group customer benefits govern which services are covered, which are excluded, and which are subject to benefit limits and which require preauthorization. Members and providers should consult the member's benefit information or contact Capital BlueCross for benefit information.

VII. DISCLAIMER

[TOP](#)

Capital BlueCross's medical policies are developed to assist in administering a member's benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member's benefit information, the benefit information will govern. Capital BlueCross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS TIBIAL NERVE STIMULATION
POLICY NUMBER	MP-1.134

VIII. CODING INFORMATION

[TOP](#)

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Medically Necessary:

CPT Codes®							
64566							

Current Procedural Terminology (CPT) copyrighted by American Medical Association. All Rights Reserved.

ICD-10-CM Diagnosis Codes	Description
N32.81	Overactive bladder
N39.41	Urge incontinence
N39.42	Incontinence without sensory awareness
N39.43	Post-void dribbling
N39.44	Nocturnal enuresis
N39.45	Continuous leakage
N39.46	Mixed incontinence
N39.490	Overflow incontinence
N39.491	Coital incontinence
N39.492	Postural (urinary) incontinence
N39.498	Other specified urinary incontinence
R32	Unspecified urinary incontinence
R33.0	Drug induced retention of urine
R33.8	Other retention of urine
R33.9	Retention of urine, unspecified
R35.0	Frequency of micturition
R39.15	Urgency of urination

IX. REFERENCES

[TOP](#)

ACOG Practice Bulletin No. 155: Urinary Incontinence in Women. Obstet Gynecol. Nov 2015;126(5):e66-81. PMID 26488524

Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Percutaneous tibial nerve stimulation for the treatment of voiding dysfunction. TEC Assessments. 2013;Volume 28:Tab 10.

POLICY TITLE	PERCUTANEOUS TIBIAL NERVE STIMULATION
POLICY NUMBER	MP-1.134

Blue Cross Blue Shield Association Medical Policy Reference Manual. 7.01.106, Percutaneous Tibial Nerve Stimulation. April 2018.

Boudaoud N, Binet A, Line A, et al. Management of refractory overactive bladder in children by transcutaneous posterior tibial nerve stimulation: A controlled study. J Pediatr Urol. Jun 2015;11(3):138 e131-110. PMID 25979217

Burton C, Sajja A, Lathe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn. Nov 2012;31(8):1206-1216. PMID 22581511

Edenfield AL, Amundsen CL, Wu JM, et al. Posterior tibial nerve stimulation for the treatment of fecal incontinence: a systematic evidence review. Obstet Gynecol Surv. May 2015;70(5):329-341. PMID 25974730

Eftekhari T, Teimoori N, Miri E, et al. Posterior tibial nerve stimulation for treating neurologic bladder in women: a randomized clinical trial. Acta Med Iran. Nov 2014;52(11):816-821. PMID 25415813

Finazzi-Agro E, Petta F, Sciobica F, et al. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol. Nov 2010;184(5):2001-2006. PMID 20850833

Gaspard L, Tombal B, Opsomer RJ, et al. [Physiotherapy and neurogenic lower urinary tract dysfunction in multiple sclerosis patients: a randomized controlled trial]. Prog Urol. Sep 2014;24(11):697-707. PMID 25214451

Gaziev G, Topazio L, Iacovelli V, et al. Percutaneous Tibial Nerve Stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review. BMC Urol. Nov 25 2013;13:61. PMID 24274173

George AT, Kalmar K, Sala S, et al. Randomized controlled trial of percutaneous versus transcutaneous posterior tibial nerve stimulation in faecal incontinence. Br J Surg. Feb 2013;100(3):330-338. PMID 23300071

Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. May 2015;193(5):1572-1580. PMID 25623739

Gungor Ugurlucan F, Onal M, Aslan E, et al. Comparison of the effects of electrical stimulation and posterior tibial nerve stimulation in the treatment of overactive bladder syndrome. Gynecol Obstet Invest. Nov 16 2013;75(1):46-52. PMID 23171636

Horrocks EJ, Thin N, Thaha MA, et al. Systematic review of tibial nerve stimulation to treat faecal incontinence. Br J Surg. Apr 2014;101(5):457-468. PMID 24446127

Knowles CH, Horrocks EJ, Bremner SA, et al. Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment of faecal incontinence in adults (CONFIDeNT): a double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial. Lancet. Oct 24 2015;386(10004):1640-1648. PMID 26293315

Levin PJ, Wu JM, Kawasaki A, et al. The efficacy of posterior tibial nerve stimulation for the treatment of overactive bladder in women: a systematic review. Int Urogynecol J. Nov 2012;23(11):1591-1597. PMID 22411208

POLICY TITLE	PERCUTANEOUS TIBIAL NERVE STIMULATION
POLICY NUMBER	MP-1.134

MacDiarmid SA, Peters KM, Shobeiri SA, et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol. Jan 2010;183(1):234-240. PMID 19913821

Monteiro ES, de Carvalho LB, Fukujima MM, et al. Electrical stimulation of the posterior tibialis nerve improves symptoms of poststroke neurogenic overactive bladder in men: a randomized controlled trial. Urology. Sep 2014;84(3):509-514. PMID 25168524

Moosdorff-Steinhauser HF, Berghmans B. Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: A systematic review. NeuroUrol Urodyn. Mar 2013;32(3):206-214. PMID 22907807

Perissinotto MC, D'Ancona CA, Lucio A, et al. Transcutaneous tibial nerve stimulation in the treatment of lower urinary tract symptoms and its impact on health-related quality of life in patients with Parkinson disease: a randomized controlled trial. J Wound Ostomy Continence Nurs. Jan-Feb 2015;42(1):94-99. PMID 25549314

Peters K, Carrico D, Burks F. Validation of a sham for percutaneous tibial nerve stimulation (PTNS). NeuroUrol Urodyn. Jul 31 2009;28(1):58-61. PMID 18671297

Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. Apr 2010;183(4):1438-1443. PMID 20171677

Peters KM, Carrico DJ, Wooldridge LS, et al. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol. Jan 2013;189(6):2194-2201. PMID 23219541

Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. Sep 2009;182(3):1055-1061. PMID 19616802

Preyer O, Umek W, Laml T, et al. Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: a randomised controlled trial. Eur J Obstet Gynecol Reprod Biol. Aug 2015;191:51-56. PMID 26073262

Schneider MP, Gross T, Bachmann LM, et al. Tibial nerve stimulation for treating neurogenic lower urinary tract dysfunction: a systematic review. Eur Urol. Nov 2015;68(5):859-867. PMID 26194043

Schreiner L, dos Santos TG, Knorst MR, et al. Randomized trial of transcutaneous tibial nerve stimulation to treat urge urinary incontinence in older women. Int Urogynecol J. Sep 2010;21(9):1065-1070. PMID 20458465

Shamliyan T, Wyman J, Kane RL. Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness (Comparative Effectiveness Review No. 36). Rockville, MD: Agency for Healthcare Research and Quality; 2012.

Stewart F, Gameiro LF, El Dib R, et al. Electrical stimulation with non-implanted electrodes for overactive bladder in adults. Cochrane Database Syst Rev. Dec 09 2016;12: Cd010098. PMID 27935011

Thin NN, Taylor SJ, Bremner SA, et al. Randomized clinical trial of sacral versus percutaneous tibial nerve stimulation in patients with faecal incontinence. Br J Surg. Mar 2015;102(4):349-358. PMID 25644291

POLICY TITLE	PERCUTANEOUS TIBIAL NERVE STIMULATION
POLICY NUMBER	MP-1.134

Vecchioli-Scaldazza C, Morosetti C, Berouz A, et al. Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study. Gynecol Obstet Invest. Mar 28 2013;75(4):230-234. PMID 23548260

X. POLICY HISTORY

[TOP](#)

MP 1.034	CAC 4/24/2012 New Policy. Adopted BCBSA. Posterior tibial nerve stimulation for voiding dysfunction is considered investigational.
	10/8/12 Medicare variation added to indicate procedure code 64566 Posterior tibial neurostimulation, percutaneous stimulation, including programming, is considered Medically Necessary for Sr Blue HMO and Sr Blue PPO.
	6/4/13 CAC Consensus list review. Administrative code review complete.
	6/19/13 Administrative Change: Changed Medicare variation to reference LCD L33083 effective 8/1/13 rather than L31686
	CAC 3/25/14 Consensus. No change to policy statements. References updated. Rationale section added. Coding reviewed.
	CAC 3/24/15 Minor revision. Title changed to Percutaneous Tibial Nerve Stimulation. “Posterior” changed to “percutaneous” in existing policy statement. Policy statement edited to investigational for all indications with bullet points for urinary and fecal incontinence. Reference and rationale updated. Coding reviewed.
	11/2/15 Administrative change. LCD number changed from L33083 to L35011 due to Novitas update to ICD-10
	CAC 3/29/16 Consensus review. No changes to the policy statements. References and rationale updated. Coding reviewed.
	Admin Update 1/1/17 Variation reformatting.
	CAC 5/23/17 Consensus. No change to policy statements. References reviewed. Coding Reviewed.
	1/1/18 Admin Update: Medicare variations removed from Commercial Policies.
	2/26/18 Consensus review. No change to the policy statement. References reviewed.
	4/26/18 Minor review. Revised policy statements for use of PTNS in OAB syndrome that has failed behavioral and pharmacologic therapy. In these patients, PTNS is considered medically necessary as an initial course of therapy and maintenance therapy for individuals who respond to initial course. Updated references and background. Condensed rationale. Coding Updated.

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS TIBIAL NERVE STIMULATION
POLICY NUMBER	MP-1.134

[Top](#)

Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company[®], Capital Advantage Assurance Company[®] and Keystone Health Plan[®] Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies.